Reasons for initiating secondary therapy for chronic GVHD
| Reasons . | No. of patients (%) . | |
|---|---|---|
| BMT (n = 18) . | PBSCT (n = 31) . | |
| a. Progressive chronic GVHD in existing site(s) | 7 (39) | 9 (29) |
| b. New site of chronic GVHD | 0 (0) | 7 (22) |
| c. Unimproved chronic GVHD | 3 (17) | 3 (10) |
| d. a and b | 4 (22) | 11 (35) |
| e. b and c | 2 (11) | 1 (5) |
| f. Toxicity plus c or d | 2 (11) | 0 (0) |
| Reasons . | No. of patients (%) . | |
|---|---|---|
| BMT (n = 18) . | PBSCT (n = 31) . | |
| a. Progressive chronic GVHD in existing site(s) | 7 (39) | 9 (29) |
| b. New site of chronic GVHD | 0 (0) | 7 (22) |
| c. Unimproved chronic GVHD | 3 (17) | 3 (10) |
| d. a and b | 4 (22) | 11 (35) |
| e. b and c | 2 (11) | 1 (5) |
| f. Toxicity plus c or d | 2 (11) | 0 (0) |